Denosumab (anti-RANK ligand) (AMG-162, Prolia, Xgeva) is a fully human monoclonal antibody that selectively inhibits primate RANKL. Denosumab inhibits the ability of human RANKL (143–317) to stimulate the formation of osteoclasts derived from murine RAW 264.7 cells with an IC50 value of 1.64 nM.